Instituto Médico Damic S.R.L.
Instituto médico DAMIC es un centro pionero en investigación clínica de la ciudad de Córdoba, Argentina.Select an option
I am a doctor
I am a sponsor
Specializations
Taquicardia supraventricular paroxística
Enfermedad de Crohn
Colitis ulcerosa
Obesidad
Cardiovascular
Diabetes
Our team
Medical staff
Genaro Peiretti
Jimena María Martinez
Boris Bertino
Carlos Roberto Choquet
Victor Hugo Cambursano
Manuel Alvarez
Pablo Nicolas Guzman
Susana Bertola
Carolina Andrea Pujales Baluszka
Paula Tinnirello
Adriana Villarino
Alberto Lorenzatti
Luis Guzmán
Diego Felipe Martinez
Felipe Martinez
Angeles Amieva
Maria de los Angeles Calabrese
Gerardo García Bonetto
Raquel Bauducco
Marcela Flores
Jaquelina Erazo
Lorena Fernandez
Veronica Tinnirello
Alexis Cazaux
Angelica Baima
Miriam Rossetti
Esteban Donaire
Candela Garcia Carot
Open studies
Cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event - AZURE-Outcomes - AstraZenecaSee more
Heart failure
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) - AURORA-HFpEF - Bristol-Myers SquibbSee more
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function - BalanceD-HF - AstraZenecaSee more
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Schizophrenia
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder - ENLIGHTEN-Youth - Alkermes, Inc.See more
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) - CONNEX-1 CONNEX-2 CONNEX-3 - Boehringer IngelheimSee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function - BalanceD-HF - AstraZenecaSee more
Alzheimer disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) - MINDSET 2 - Bristol-Myers SquibbSee more
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) - ADAGIO-2 - Bristol-Myers SquibbSee more
Depression
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms - Janssen Research & Development, LLCSee more
Pulmonary fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Bipolar disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder - ENLIGHTEN-Youth - Alkermes, Inc.See more
